A5033152107- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
- Medication Adherence and Compliance
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Genetic factors in colorectal cancer
- Health Systems, Economic Evaluations, Quality of Life
- Breast Lesions and Carcinomas
- Brain Metastases and Treatment
- Medical and Health Sciences Research
- Childhood Cancer Survivors' Quality of Life
- Estrogen and related hormone effects
- Chemotherapy-related skin toxicity
- Health Literacy and Information Accessibility
- Neutropenia and Cancer Infections
- Management of metastatic bone disease
- Advances in Oncology and Radiotherapy
- Cancer Genomics and Diagnostics
- Cancer-related cognitive impairment studies
- CNS Lymphoma Diagnosis and Treatment
Johannes Gutenberg University Mainz
2009-2010
AstraZeneca (Germany)
2009-2010
Philipps University of Marburg
2010
Ecologic Institute
2010
Klinikum rechts der Isar
2007
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at last two ABC conferences (ABC 6 in 2021, virtual, and 7 2023, Lisbon, Portugal), organized by Global Alliance. It provides main recommendations on how to best manage patients with advanced breast cancer (inoperable locally or metastatic), of all subtypes, as well palliative supportive care. These are based available evidence expert opinion when a higher level is lacking. Each guideline...
Abstract This yearʼs 18th St. Gallen (SG) consensus conference on the treatment of early breast cancer (SGBCC: International Breast Cancer Conference) focused practice-oriented questions. The individual situation and risk-benefit assessment were discussed in great detail. As previous years, a German working group leading experts presented results international SGBCC 2023 against background recommendations – especially updated Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) for...
Background: Chronic treatment sequelae may substantially reduce the long-term quality of life in breast cancer survivors. Methods: We report a comprehensive Web-based survey on presence side effects adjuvant anti-breast therapy 1,506 patients who had been diagnosed with primary at least 1 year before. Results: Fatigue, depression, depressive mood, concentration deficit, pain, changes mucosa and skin appendages, as well symptoms peripheral neuropathy were most prevalent reported complaints....
Electronic health (eHealth) and mobile communication-based care (mHealth) applications have been increasingly utilized in medicine over the last decade, facilitated improved adherence to therapy regimens patients with chronic conditions. Due long duration of breast cancer therapy, course disease metastatic cancer, a need for more intensified physician-patient communication has emerged. Various support mechanisms, including new media such as mHealth eHealth, proposed this purpose.The aim...
The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14–16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based available evidence and ensure that all patients worldwide receive adequate access new therapies. This year, conference focused developments study results with hormone receptor-positive/HER2-negative as well precision medicine. As previous years, patient advocates from around world were...
Abstract As part of the COGNITION diagnostic registry program, residual tumor material after neoadjuvant therapy (NAT) patients with early breast cancer (eBC), who are still at high-risk for relapse NAT, is analyzed by next generation sequencing to identify biomarkers and actionable alterations. This strategy aims stratify subsequent genomics-guided therapies reduce significant risk metastatic dissemination hence improve disease-free survival. COGNITION-GUIDE a multicenter umbrella...
Abstract The rationale behind the “International Consensus Conference for Advanced Breast Cancer” (ABC) is to standardize treatment of patients with advanced or metastatic breast cancer worldwide using an evidence-based approach. aim also ensure that in all countries receive adequate based on current recommendations and standards. 7th International Cancer (ABC7) took place from November 9 12, 2023 Lisbon/Portugal. ABC7 focused disease as well locally inflammatory cancer. Special topics...
The results of the international St. Gallen Consensus Conference for treatment patients with primary breast cancer were discussed this year by a working group leading experts in view therapy recommendations everyday clinical practice Germany. Three are also members year's panel. comparison annually updated AGO 2019 as well S3 guideline is useful, since panel represent opinions from various countries and disciplines. based on evidence-based research literature. This 16th conference featured...
The first International Consensus Conference for Advanced Breast Cancer (ABC1) took place 10 years ago in November 2011. rationale was - and still is to standardize treatment of advanced breast cancer (ABC) based on the available evidence ensure that worldwide all patients receive adequate access new therapies.The 6th ABC (ABC6) from 4 6, 2021 a purely online format, due COVID-19 pandemic. In present manuscript, working group German experts comments voting results ABC6 panelists regarding...
<b><i>Background:</i></b> The “International Consensus Conference for Advanced Breast Cancer” was initiated more than 10 years ago. rationale to standardize treatment of advanced breast cancer (ABC) based on available evidence and ensure that all ABC patients worldwide receive adequate access new therapies. <b><i>Topics ABC7:</i></b> 7th International (ABC7) took place from November 9 11, 2023 – as in previous Lisbon/Portugal. ABC7 focused not...
Over the past few years, there have been many developments in treatment of advanced breast cancer; these incorporated into national and international guidelines, resulting an improved prognosis for patients. The 6th International Consensus Conference Advanced Breast Cancer (ABC6) was held November 2021. aim is to standardize cancer based on a high level evidence, make new options accessible all In this article we discuss ABC6 consensus context German compare it with clinical practice...
The Advanced Breast Cancer Third International Consensus Conference on the diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, November 5-7, 2015. This year's conference (ABC3) was focused metastatic (stage IV), as it 4 years ago at first consensus meeting (ABC1). A matter particular interest patients' perspective. Thus, patient-relevant issues were addressed by discussions, such those goals, quality life, care long-term survivors ('survivorship issues'), coping...
The Advanced Breast Cancer Fourth Consensus (ABC4) on diagnosis and treatment of advanced breast cancer (ABC) again took place in Lisbon, November 2-4, 2017, was chaired by Fatima Cardoso, MD, PhD. This year's contents focused very much new developments the ABC. For example, significance inhibition cyclin-dependent kinases 4 6 (CDK4/6) hormone receptor (HR)-positive ABC, dual antibody blockade human epidermal growth factor 2 (HER2)-positive poly(ADP-ribose) polymerase (PARP) triple-negative...
The Patient's Anastrozole Compliance to Therapy (PACT) program is a large randomized study designed assess whether the provision of educational materials (EM) could improve compliance with aromatase inhibitor therapy in postmenopausal women early, hormone receptor-positive breast cancer.The PACT presented large, homogeneous dataset. baseline analysis included patient demographics and initial treatments perceptions about treatment quality life.Overall, 4,923 patients were enrolled at 109...
Breast cancer patients' self-understanding of their disease can impact quality life (QoL); the relationship between compliance and QoL is poorly understood.The Patient's Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated effect additional patient information material (IM) packages on with adjuvant aromatase inhibitor (AI) therapy in postmenopausal women hormone receptor-positive early breast cancer. The subanalysis presented here examined IM...
PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in multicenter setting university community hospitals. PATIENTS AND METHODS We tested hybrid protocol two non-cross-resistant regimens, cyclophosphamide, epirubicin, vincristine, prednisolone (CEOP) ifosfamide, etoposide (VP-16), methotrexate, dexamethasone (IMVP-Dexa) given every fourth week, three to six times according response, patients with untreated intermediate- high-grade...
Abstract This yearʼs 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) title “Customizing local and systemic therapies for women early breast cancer” focused challenge targeting treatment cancer more specifically to individual disease situation each patient. As in previous years, a German working group leading experts discussed results international SG-BCC 2021 context guideline. It is helpful compare SG recommendations recently updated...